In a mouse model, a HER2-directed CAR incorporating a pH-restricted binding domain showed significant expansion of CAR-T cells and regression of HER2-positive tumor cells.154 However, despite the development of CAR-T products activated by acidic pH, most of these products remain in preclinical or clinical trial stages, and their safety profile continues to face significant challenges. This evidence concerns the gene ERBB2 and neoplasm.